Results 31 to 40 of about 8,927 (183)

Determinants of Difficult‐to‐Manage and Treatment‐Refractory Axial Spondyloarthritis: A Cross‐Sectional Analysis Within a Longitudinal Cohort

Arthritis &Rheumatology, EarlyView.
Objective The purpose of this study was to estimate the prevalence of difficult‐to‐manage (D2M) and treatment‐refractory (TR) axial spondyloarthritis (axSpA) and to identify factors associated with D2M and TR disease in a longitudinal cohort. Methods We performed a cross‐sectional analysis on data from the Schroeder Arthritis Institute Spondylitis ...
Patricia Remalante‐Rayco, Laura Passalent, Tina Chim, Hannah Vijayan, Manal Alnasser, Zeynep Baskurt, Robert D. Inman, Nigil Haroon, Denis Poddubnyy   +8 more
wiley   +1 more source

Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT

Arthritis Research & Therapy, 2021
Background To investigate the efficacy of secukinumab in patients with active non-radiographic axial spondyloarthritis (nr-axSpA) grouped by disease activity as assessed by C-reactive protein (CRP) levels and/or magnetic resonance imaging (MRI) scores ...
Jürgen Braun, Ricardo Blanco, Helena Marzo-Ortega, Lianne S. Gensler, Filip van den Bosch, Stephen Hall, Hideto Kameda, Denis Poddubnyy, Marleen van de Sande, Anna S. Wiksten, Brian O. Porter, Abhijit Shete, Hanno B. Richards, Sibylle Haemmerle, Atul Deodhar   +14 more
doaj   +1 more source

Association of Gender, Diagnosis, and Obesity With Retention Rate of Secukinumab in Spondyloarthropathies: Results Form a Multicenter Real-World Study

Frontiers in Medicine, 2022
Background: Secukinumab has been shown effective for psoriatic arthritis (PsA) and axial spondylarthritis (AxSpA) in randomized trials. The aim of this study was to analyze baseline patient and disease characteristics associated with a better retention ...
Alicia García-Dorta, Paola León-Suarez, Sonia Peña, Marta Hernández-Díaz, Carlos Rodríguez-Lozano, Enrique González-Dávila, María Vanesa Hernández-Hernández, Federico Díaz-González, Federico Díaz-González   +8 more
doaj   +1 more source

First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801

British Journal of Clinical Pharmacology, EarlyView.
Aim The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), food‐effect (FE) and pharmacodynamics (PD) of an oral tyrosine kinase‐2 (TYK2)/Janus kinase‐1 (JAK1) inhibitor, SDC‐1801, in healthy adult participants. Methods This first‐in‐human study randomized 95 male and female participants.
Chris Brearley, Sam Francis, John Reader, Judi Proctor   +3 more
wiley   +1 more source

Use of Patient Reported Outcome Measurements Information in Clinical Practice in Spain for the Clinical Management of Psoriasis Patients—Summer Project

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Routine collection of patient perspectives about psoriasis and its treatment through patient reported outcome measurements (PROMs), alongside clinician reported outcome measurements (CROMs), may improve clinical outcomes and facilitate shared decision making.
Jaime Notario, Jorge Magdaleno‐Tapial, Raquel Rivera, Josep Riera‐Monroig, Conrad Pujol, Cynthia Novella, Manuel Cuervas‐Mons, Pablo de la Cueva   +7 more
wiley   +1 more source

JAK Inhibitors in Psoriatic–Atopic Dermatitis Overlap: A Four‑Case Series

JEADV Clinical Practice, EarlyView.
ABSTRACT Overlap between psoriasis and atopic dermatitis (AD) poses diagnostic and therapeutic challenges; monoclonal antibodies targeting a single axis may improve one component while worsening the other [1]. Janus kinase (JAK) inhibitors act pleiotropically and may provide simultaneous control of psoriatic and eczematous inflammation [2].
Eleonora Bongiovanni, Francois Rosset, Isotta Giunipero di Corteranzo, Lorenzo Bellando, Rebecca Senetta, Simone Ribero, Pietro Quaglino   +6 more
wiley   +1 more source

Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with secukinumab: primary results from a randomized controlled phase-IIIb trial

Therapeutic Advances in Musculoskeletal Disease, 2021
Background: This study aimed to evaluate the efficacy and safety of secukinumab 150 mg compared with placebo in the management of spinal pain and disease activity in patients with axial spondyloarthritis (axSpA) at Week 8 and up to Week 24.
Denis Poddubnyy, Effie Pournara, Agnieszka Zielińska, Asta Baranauskaite, Alejandro Muñoz Jiménez, Sanchayita Sadhu, Barbara Schulz, Michael Rissler, Chiara Perella, Helena Marzo-Ortega   +9 more
doaj   +1 more source

Paradoxical Alopecia Areata Induced by IL‐17 and IL‐23 Inhibitors: A Systematic Review

JEADV Clinical Practice, EarlyView.
This systematic review identifies consistent clinical patterns of alopecia areata associated with IL‐17 and IL‐23 inhibitors, most frequently involving secukinumab and ustekinumab. Disease severity varied widely, and management often required biologic discontinuation or therapeutic switching.
Isabella Kamholtz, Simonetta I. Gaumond, Joaquin J. Jimenez   +2 more
wiley   +1 more source

Therapeutic Challenges in Managing Coexisting Hidradenitis Suppurativa and Squamous Cell Carcinoma: A Clinical Case Study

JEADV Clinical Practice, EarlyView.
ABSTRACT Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder affecting intertriginous areas. Long‐standing HS can undergo malignant transformation into squamous cell carcinoma (SCC), particularly in the perineal and gluteal regions. We report a 54‐year‐old man with severe, treatment‐refractory HS complicated by an aggressive verrucous
Michael Zolotas, Tereza Jakovljevicova, Kamran Ghoreschi, Kerstin Kusch, Marisa Klemp, Robert Sabat, Georgios Kokolakis   +6 more
wiley   +1 more source

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study

Arthritis Research & Therapy, 2018
Background Secukinumab has demonstrated sustained improvement in the signs and symptoms of psoriatic arthritis (PsA) over 2 years in the FUTURE 2 study (NCT01752634).
L. C. Coates, D. D. Gladman, P. Nash, O. FitzGerald, A. Kavanaugh, T. K. Kvien, L. Gossec, V. Strand, L. Rasouliyan, L. Pricop, K. Ding, S. M. Jugl, C. Gaillez, on behalf of the FUTURE 2 study group   +13 more
doaj   +1 more source